Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
Nearly half of the patients who were started on GLP1RA, a treatment intended for indefinite use, stopped taking GLP1RA within 2 years. Patients who stopped treatment experienced similar weight loss to those who never started treatment. For real-world patients who stayed on treatment for 2 years, a lower TWL% was observed than previously reported in clinical trials.
Authors
- Andrea Bródy (ORCID: https://orcid.org/0000-0001-8085-8418)
- Karol Prieto (ORCID: https://orcid.org/0000-0002-4622-0258)
- Amy Wetzel
- Jochen Schmitt (ORCID: https://orcid.org/0000-0003-0264-0960)
- Yen‐Yi Juo (ORCID: https://orcid.org/0000-0003-4862-9636)
- Mona Abdel‐Bary
Institutions
- Allina Health (US)
- Medica (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-19
- DOI
- https://doi.org/10.1111/dom.16331
- Citations
- 5
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 6.47